Podcasts about Merck

Send Zorba a message!Zorba's thoughts on the groundbreaking mRNA therapeutic vaccine to combat melanoma.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

A battle erupts between RFK Jr. and Pennsylvania Governor Josh Shapiro over two “measles-associated” deaths, vaccine misinformation, and the use of abortion-derived fetal cell lines in MMR production.Jefferey Jaxen investigates Merck's claim that fulfilling President Trump's order to split the MMR vaccine could take up to a decade. Plus, Fauci launches a legal defense fund as scrutiny of the COVID lab-leak cover-up intensifies.As closing arguments conclude in the Lindsay Clancy trial, Del sits down with board-certified clinical psychologist Dr. Roger McFillin to examine Clancy's psychiatric-drug history and ask whether the pharmaceutical industry belongs on trial, too.Then, Del checks in with MAPS President Dr. James Neuenschwander about a MAPS physician's appointment to the NIH and the upcoming MAPS conference.Guests: Aaron Siri, Esq., James Neuenschwander, M.D., Roger K. McFillin, Psy.D., ABPPAirdate: August 27, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

P.M. Edition for Aug. 26. Tech reporter Meghan Bobrowsky tells us why the Meta settlement could change how teenagers use some of the world's most popular apps. Plus, the FDA approves a milestone therapy for pancreatic cancer. WSJ reporter Xavier Martinez discusses how the nearly $40,000-a-month drug from Revolution Medicines could change patient outcomes of one the deadliest cancers. And the FBI shuts down a sprawling hacking network linked to China that targeted NASA, the Federal Reserve and critical infrastructure. Sabrina Siddiqui hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Brainstorm, Sam, Nick, and Brett break down Merck and Moderna's positive Phase 3 results for a personalized mRNA cancer vaccine, a treatment custom-built from each patient's own tumor that cut mortality from advanced melanoma by roughly 50% versus the standard of care. The team digs into cost, manufacturing scale, and why the capital poured into mRNA during COVID may be paying off in oncology. Then Brett reports back from a weekend with Grok Bot, which recovered $75 of his wife's forgotten escrow money on its first task, and the team debates why multiplayer agents could be the real threat to Microsoft's enterprise moat.Key Points From This Episode:How a custom mRNA vaccine trains the immune system against a patient's own tumor, and what Phase 3 melanoma results could mean for other cancersWhy $200K–$300K per treatment limits early use, and what we believe has to change for personalized oncology to scaleWhy agents that live inside team chat, not one-on-one, may be the real disruption to Microsoft and SlackIf you know ARK, you know we focus on long-term innovation. But that doesn't mean we ignore breaking news. Every day, we debate the latest developments in tech and markets. Now, we're bringing those conversations to you in “The Brainstorm,” a co-production from ARK, WOLF, and Public. Tune in weekly for our quick takes on what's shaping innovation right now.Learn more about WOLF: https://wolf.financialLearn more about Public: https://public.com/Disclosure: http://arkinv.st/39rzF94

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über die Zoll-Eskalation in Nordamerika, die große Krypto-Erholung und was sonst noch so wichtig wird in dieser Woche. Außerdem geht es um Merck & Co., Johnson & Johnson, Robinhood, Coinbase, Strategy, Tesla, Freeport-McMoRan, Salzgitter, Thyssenkrupp, Aurubis, Meta, Motorola Solutions, Berkshire Hathaway, Visa, Mastercard, Cintas, Home Depot, Fidelity National Information Services, Palantir, RTX, Northrop Grumman, State Street SPDR S&P U.S. Technology Select Sector (WKN: A14QB5), iShares U.S. Treasury Bond ETF (WKN: A2JKTZ), iShares GSCI Commodity Dynamic Roll Strategy ETF (WKN: A14SNM), iShares Physical Gold EUR Hedged (WKN: A3GX4G), Invesco Physical Gold EUR Hedged (WKN: A28QBG), Xetra-Gold (WKN: A0S9GB), EUWAX Gold Core (WKN: EWG4CR) und Euwax Gold II (WKN: EWG2LD). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Diese Folge enthält Werbung für Smartbroker+. Depot eröffnen, 30 € ETF als Bonus sichern und aus tausenden ETFs wählen. Smartbroker+ macht Investieren einfach. Alle Informationen gibt es unter: https://get.smartbrokerplus.de/triple-aaa-podcast2/ Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

What does mayhem in the bond market have to do with AI? And why are discount retailers getting a boost? Plus, how did Moderna help lift healthcare stocks? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does mayhem in the bond market have to do with AI? And why are discount retailers getting a boost? Plus, how did Moderna help lift healthcare stocks? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In his weekly clinical update, Daniel Griffin and Vincent Racaniello are perplexed by the state of global public health as malaria, cholera and other infectious diseases are spread by civil warfare, the lack of manpower at the CDC to implement Congressional health programs, the first cancer mRNA vaccine resulting from a Merck and Moderna collaboration, how cyclosporiasis and screwworm outbreaks continue, FDA approval of new drugs against screwworm and critical policy decisions to control the Ebola outbreak in the Congo, before Dr. Griffin deep dives into the measles outbreak, recent statistics on RSV, influenza, SARS-CoV-2 infections and the drop in vaccination rates in the US, how schools are the source of measles infection, how vaccines only prevent severe disease not transmission as trafficking of measles on vaccinated people begins to be acknowledged, to access and pay for Paxlovid, what to know about the mRNA flu vaccine, where to go for answers about long COVID-19, clinical guidelines for treating long COVID, three myths of respiratory disease and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Myanmar's Civil War Pushes Infectious Disease Over Its Borders (NY Times) Alzheimer's disease (AP News) US adult cigarette smoking rate hits another all-time low (AP News) The CDC has zombie programs. Congress funds them, but few people are left to do the work (AP News) Merck, Moderna's personalized cancer vaccine slows recurrence in phase 3, setting up approval push (FIERCE Biotech) Surveillance of Cyclosporiasis (CDC: Cyclosporiasis) Infectious DiseaseOutbreaks (Michigan: Health & Human Services) Cyclosporiasis Cases in North Carolina (North Carolina: Division of Public Health) Cyclospora Infection (Cyclosporiasis) (NYC Health) Missouri Communicable Disease Report (2026) (Missouri Health) TWiP 285: Why is cyclospora hard to contain: Parasitologists explain the 2026 US outbreak (microbeTV:TWiP) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newsroom) FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies (FDA) FDA grants emergency use authorization for another New World screwworm treatment (CIDRAP) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Three Months into the Bundibugyo Ebola Outbreak: Now is the time for Decisive Action (AfricaCDC) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Do vaccinated cases transmit measles? A systematic review and meta-analysis (Expert Review of Vaccines) County, district and community-level measles transmission in the United States in 2013−2025 (Nat Medicine) Dozens of States Tried to Roll Back Vaccine Laws. Here's How They Fared. (NY Times) More U.S. Parents Opting Children Out of Vaccine Requirements, C.D.C. Reports (NY Times) The threat of more, expanded measles outbreaks looms with start of school (CIDRAP) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: clift notes (CDC FluView) What to Know About the mRNA Flu Vaccine, Newly Approved by the FDA (JAMA) Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial (LANCET) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis (LANCET) A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study (LANCET) Real-world studies show RSV immunizations protect newborns in their first year of life (CIDRAP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Trump Officials Falsely Connect Covid Vaccines to Miscarriage (NY Times) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Beyond the acute illness: three myths about viral respiratory infection (JID) Reaching out to US house representative Letters read on TWiV 1350 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Moderna stock surged over 160% after their personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, reported a successful trial for melanoma. But after the COVID-19 vaccine debacle, can mRNA technology be trusted? Salty Cracker joins Dr. Drew LIVE to discuss the new mRNA cancer treatment, ex Dr. Fauci adviser David Morens pleading guilty to conspiracy, the now-over-$900k GoFundMe for accused murderer Lindsay Clancy (allegedly benefiting her parents), and Roysha / Royce White's WNBA draft bid. Salty Cracker is an uncensored clown world commentator known for breaking the Left with satire, shame, and ridicule. He is active on Rumble as TheSaltyCracker. Follow at https://x.com/saltycracker9 「 SUPPORT OUR SPONSORS 」 • BIOPRO - BioPro+® is a natural formula of growth factors and peptides that support how you look, feel & perform. Learn more at ⁠⁠⁠https://drdrew.com/biopro⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • CHAPTER - For free and unbiased Medicare help, dial (218) 521-2472 to speak with my trusted partner, Chapter, or go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://askchapter.org/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan's contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don't directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (8/21/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v7cb2wc","div":"rumble_v7cb2wc"}); Source Links (In Chronological Order): Sam Husseini Interview - Can A Corrupt System Be Changed From Within? New Tab (20) Brian Cates - Political Columnist & Pundit on X: "@L08818 I slowly came to realize on hanging out with Ron Paul enthusiasts that they don't want to reform the system, drive out the corruption, and restore the country. The want to...and they told me this several times, but back then I didn't really believe them...BURN IT ALL DOWN AND" / X (20) The Last American Vagabond on X: "What an absolutely disingenuous coward you are @L08818. https://t.co/31KRfbLcxZ" / X (20) SheThinksFreely (@L08818) / X (20) SheThinksFreely on X: "@TLAVagabond Bro GTFOH w this stupid sh*t Anarchy is anti American You traitorous piece of excrement" / X (20) SheThinksFreely on X: "

Hey this is Alex, welcome to... the chillest week in AI, since ... a long time. Chill, if you consider Moderna and MERK announcing a cancer vaccine and surging 115% in a day, a chill week. This week, the only two model drops we really saw came from the excellent Z.ai folks, they announced GLM 5.3, API only for now, and an amazing tiny release of Qwen 3.89 27B. In other big AI news, OpenAI announced they are pausing RL efforts (Reinforcement Learning) to focus on security and alignment post the scary AI Swarms hacking incident, dedicating up to 20% of compute towards reviewing agent thinking processes, and Stripe buying OpenRouter for a reported $8B! Sometimes the chill weeks are actually good, we're able to chat about how we use AI, what changed for us, and give our guests a bit of breathing room. This week, I invited Francesco from CUA to talk about computer use in open source + their new history plugin, Bin from HeyGen to talk about HyperFrames, a way for your agents to create videos and a breaking news guest, Jeff Huber from Chroma jumped on to talk about their new Foundations release, a unified memory for your agents! This was a great episode, I hope you'll like it, it's up here on Substack and everywhere you get your pod (Spotify, Youtube, Apple Podcasts). ThursdAI - Highest signal weekly AI news show is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Are we being fed slop again? (Is Claude dumb again?)Before we get to releases, this week on the show, I complained, again, that I feel my AI's are degrading. If this feels like de-ja-vu to you, it's because the same happened a year ago in September 2025 (and Anthropic admitting this 2 weeks later), and ... now this happens with Fable?You see, I use pretty much the same prompts, every week, preparing for the show. This is partly my way to evaluate new models and compare to existing and previous ones while also bringing you the best researched weekly show in AI. Well, this week, one after another, Claude Fable, which is... like the best intelligence, gave me such poor output, that I couldn't believe what I'm seeing. First, literally ignoring instructions that say “hey, show me all the items I've collected and let me pick the most important ones”, Fable instead sent all of them to my research pipeline, without showing me. This has worked, consistently, without fail, for the past... year? maybe more! This worked with open source models, worked with GPT, and now Fable, a Mythos Level LLM, is doing the most basic dumb s**t possible, ignoring the main reason I even have this workflow. And this wasn't just a fluke either, when asked to create a run of show document, and given an example, Fable produced this... whatever this is. This is the same document and same format that Fable produced for me during AI Engineer which got me thinking “ok, this is AGI”, and here, given an example, I got a completely unusable artifact, despite direct instructions, structure and example! I got to say, given that privately this week, Anthropic disclosed that they have passed $65B in revenue, which is absolutely insane, this doesn't add up. So I figured, ok Alex, maybe this is your prompts or skills. But no, LDJ came in with some charts that show degradation, one from MarginLab.ai that shows significant lowering on number of tool calls and average runtime recently (this is for Opus 5) and And another chart from modelverify.ai model drift monitor showing drift scores.Do we have anoher Claude Gate on our hands? Is your Fable/Opus behaving weird lately? Or did you completely switched away to other models? OpenAI pausing RL and focusing on safetyLook, when we covered the HF hacking incident and then the pacing the frontier letter, I didn't imagine that results will come this fast, but this week, OpenAI publicly announced that they are pausing RL training, which is the last step of models, until they get their sandboxes in order and align the models better. We all agreed on stage that this is likely a very good move, and Peter was really awe-struck at the 20% dedication of resources towards reviewing thought processes of models. Is this a good enough response to the scary hacking incident? we'll see, but I think this is the right move from OpenAI, and still, waiting for the full postmortem on the OpenAI security incident. Open Source LLMsQwen3.8-27B ties GPT-5.6 Luna and runs on a 4090 (X, HF, Announcement)Following the release of their flagship, Alibaba dropped a model that became a community darling overnight, Qwen 3.8 with just 27B parameters. This “tiny” model scores 52 on the Artificial Analysis Intelligence Index, same score as GPT 5.6 Luna at Max reasoning and 51 on Agentic index, beating Opus 4.8 MaxAll while running at around 68t/s on a 4090 GPU, and around 40 on max via MLX, hell it even does 11t/s on Xenova's WebGPU kernels right in the browser! This model exploded on the HuggingFace hub, with tons of quants, over 152 fine-tunes, it was downloaded over 10M times overall

Israel's military has confirmed for the first time that its troops opened fire on a car carrying Hind Rajab, the five-year old Palestinian child who was killed alongside six of her relatives in Gaza in 2024. The IDF is opening a criminal investigation into the deaths, as well as those of two paramedics sent to rescue her. A separate inquiry will examine the killing of fifteen emergency and aid workers in Rafah last year. Also: after six years in the US state of California, Prince Harry and his family are moving back to the UK, but will not be undertaking royal duties. At least five people have been killed by Russian missile attacks on Kyiv in the early hours of Thursday morning. The US pharmaceutical giants, Moderna and Merck, say trials of an experimental treatment for melanoma have shown signs of success. US public debt has soared to a record 40 trillion dollars. A former Meta employee, turned whistleblower, tells a court in California that Meta CEO, Mark Zuckerberg, put growth in Facebook and Instagram before child safety. We have a special report about the gold rush in Kenya that's causing security and safety concerns. Scientists say giant whales are taking advantage of the ice disappearing from East Greenland, and shares in the Chinese robot maker, Unitree, soar as it launches its new humanoid robots.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Five-year-old Hind Rajab who was killed in Gaza, January 29th 2004, by the Israel Defense Forces (IDF) during the Gaza war. Credit: Family

Today's Headlines: Trump spent yesterday morning showing off his new White House helipad and giving an unprompted infomercial for Scott's Miracle-Gro that spiked the company's stock — a useful distraction from reporting that his aide Natalie Harp, the Human Printer, worked at the White House for a year without a security clearance because she refused until Trump personally intervened. He also TACO'd again, the Canada tariffs Trump announced at 50% were paused before they went into effect because they're "probably going to make a deal," and the US national debt hit $40 trillion for the first time, doubling in a decade, so the economic situation is going great.Surprise! We've got some great news, an mRNA vaccine to prevent skin cancer from recurring was successful in clinical trials, with Moderna and Merck potentially launching commercially next year and with possible applications to other cancers. Violent crime also dropped nearly 10% in 2025, the largest single-year decline since the FBI started tracking in 1936, with murder down 18% and robbery down 18.5%, which is the kind of news that deserves more attention than it's getting. Now back to regularly scheduled shenanigans. The Army is offering soldiers four days off to play Grand Theft Auto 6 as a re-enlistment incentive, and at least 20 have signed up, which says something about both the state of military recruitment and the anticipation for GTA 6. Elon Musk is reportedly planning to spend $100-200 million on the midterms, with a focus on helping Ken Paxton win a Texas Senate seat — Paxton has raised $9 million to James Talarico's $69 million, so Elon's money is going to be doing a lot of heavy lifting. In primary results, Trump's preferred Wyoming governor candidate lost to an experienced state legislator, and Alaska's jungle primary produced a genuinely chaotic situation where two Dan Sullivans are running — the incumbent Republican senator and a retired schoolteacher who argues he's been Dan Sullivan longer, which is technically true. And finally, Harry and Meghan are reportedly moving back to the UK with Archie and Lilibet, not as working royals, which means those HRH titles are about to get a workout. Resources/Articles mentioned: WaPo: Trump shows off his new helipad, brags about construction projects MS Now: Trump aide Natalie Harp worked at the White House without security clearance for a year  Reuters: US could cut key tariffs as part of proposed Canada deal, source says CNBC: U.S. government debt passes $40 trillion, more than doubling in a decade Variety: US Army Offering Soldiers Four Days Off to Play 'GTA 6' if They Reenlist Axios: Moderna and Merck shares soar on mRNA cancer vaccine Axios: FBI: 2025 had biggest violent-crime drop in 90 years WaPo: 8 takeaways and surprises from Florida, Wyoming and Alaska primaries Wired: Elon Musk Is Expected to Point His Money Machine at Texas Politics AP News: Prince Harry and Meghan are returning to the UK with their children, British newspaper says** Subscribe to the Betches News Room and join the Morning Announcements group chat. Go to: betchesnews.substack.com Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

In part two of Red Eye Radio with Gary McNamara and Eric Harley, the two biggest issues that most people are concerned about are vaccines and data centers. An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said Wednesday, paving the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year. Moderna shares more than doubled Wednesday, while Merck's stock hit an all-time high. Also data centers, the gigantic buildings that house the computing power behind the artificial intelligence boom, are wildly unpopular. A recent Gallup poll found that 7 in 10 Americans oppose one being built in their area. For more talk on the issues that matter to you, listen on radio stations across America Monday-Friday 12am-5am CT (1am-6am ET and 10pm-3am PT), download the RED EYE RADIO SHOW app, asking your smart speaker, or listening at RedEyeRadioShow.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode is presented by Create A Video – Artificial intelligence (and the data centers that make it possible) have helped a world-changing breakthrough in cancer treatment. So, according to the Romney Rule, this means if you oppose data center construction it means you support people dying of cancer. Sorry, but I don't make the rules.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-pete-kaliner-show--6946691/support.Subscribe to the podcast My preferred podcast platform: SpreakerAll the links to Pete's Prep are free!Get exclusive content here!Media Bias Check: GroundNews promo code!Advertising and Booking inquiries: Pete@ThePeteKalinerShow.com  

This week Merck (known as MSD in Europe) and Moderna announced that a personalised cancer vaccine had significantly improved the outcomes of melanoma patients. Is the era of the cancer vaccine, at last, upon us? What does that mean? Anne Willis, a cancer cell biologist at the Medical Research Council, joins us to discuss. In just a few weeks the Royal Society will be putting out the red carpet as the most coveted prize in non-fiction science is about to be awarded. We will be speaking weekly to the shortlisted authors for the Royal Society Trivedi Book Prize, and we are starting with Kit Chapman, author of the Age of Alchemy. Plus, Penny Sarchet has, like an alchemist of old, been scouring the most obscure texts and journals to bring us the latest science knowledge. Presenter: Tom Whipple Producers: Alex Mansfield, Tabitha Taylor Buck, Katie Tomsett, Keiran Manetta-Jones Editor: Ilan Goodman Production Co-ordinator: Jana Bennett-Holesworth

In this episode of The Canadian Investor Podcast, we break down another busy week of market news and earnings. We start with Moderna, whose stock more than doubled after the company announced positive late-stage trial results for its personalized mRNA cancer therapy developed with Merck. We discuss why the news matters for Moderna, why Merck also benefited, and why biotech investing can be so volatile. We then look at Canadian Tire’s latest quarter, including the strength at SportChek and Mark’s, the stabilization in its financial services segment, and the upcoming Triangle Rewards partnership with Tim Hortons. From there, we discuss Home Depot and Lowe’s, what their results say about the housing and renovation market, and why elevated interest rates continue to weigh on big-ticket home improvement spending. We also revisit Constellation Software after its latest earnings, including organic growth concerns, record capital deployment, and why the company says AI has not materially disrupted its business so far. Finally, we cover Air Canada’s quarter, rising airline costs, CoreWeave’s explosive AI infrastructure growth and balance sheet risk, and Klarna’s latest results after a sharp post-earnings selloff. Tickers discussed: MRNA, MRK, CTC.A.TO, HD, LOW, CSU.TO, AC.TO, CRWV, KLAR, AAPL Subscribe to Our New Youtube Channel! Check out our portfolio by going to Jointci.com Our Website Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Fiscal.ai for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

Neuroscientist and educator Jared Cooney Horvath testified before the Senate earlier this year on the impacts of classroom technology. Horvath shares his thoughts on screen time and education.Drug manufacturers Moderna and Merck say a personalized mRNA cancer vaccine plus a drug called Keytruda reduced the return and spread of melanoma in high-risk patients. Dr. Jon LaPook and trial researcher Dr. Janice Mehnert have more information.Neuroscientist and educator Jared Cooney Horvath testified before the Senate earlier this year on the impacts of classroom technology. Horvath shares his thoughts on screen time and education.For America's 250th birthday, USAA unveiled The National Military Monument in Washington, D.C., a living tribute to the more than 41 million veterans who have served the U.S. USAA Senior Vice President Rob Braggs shares that the monument will stay open through Nov. 12. Visit https://monument250.usaa360.com/ for more information. (Sponsored by USAA)Students nationwide are grappling with a new reality -- AI-generated pornography, sometimes featuring themselves or someone they know. CBS News found more than a dozen AI "nudify" apps easily accessible in app stores, some without age restrictions. Jo Ling Kent has more.The NFL is launching a new "celly" campaign to honor the tradition of touchdown celebration dances in the end zone. Jason Allen joins the Houston Texans at their training facility to learn more.

Decentralized clinical Trials (DCTs) bring some or all elements of a clinical trial closer to patients. Consent, screening, treatment administration, and more can be administered through digital technologies and local health care providers, expanding accessibility for patients who face barriers to participation in traditional single site trials. In this episode, CANCER BUZZ speaks with Erin Pierce, MSN, APRN, FNP-C, Associate Clinical Investigator and Nurse Practitioner at HonorHealth Research Institute, and Kristen Kipping-Johnsson, MPH, Director of Network Research Operations at the University of Chicago, about how each of their cancer programs are approaching DCT implementation. Their discussion explores how decentralized components, such as community-based treatment delivery, centralized research infrastructure, and hybrid trial designs, can increase participation opportunities for patients in both community and academic settings. Guests: Erin Pierce, MSN, APRN, FNP-C Associate Clinical Investigator Nurse Practitioner HonorHealth Research Institute Scottsdale, AZ   Kristen Kipping-Johnson, MPH Director of Network Research Operations University of Chicago Chicago, IL "APPs are really poised to step into that role [of investigator] and help, not take the place of physicians, but work alongside our physician colleagues and enable us to expand the abilities of research." —Erin Pierce, MSN, APRN, FNP-C "Quality of life, being able to keep patients treated closer to home, allow them to stay with the physician that diagnosed them...Those are the things that are really important to me when it comes to decentralization." —Kristen Kipping-Johnson, MPH Resources HonorHealth Research Institute's First Steps to Approaching Decentralized Clinical Trials (DCTs) University of Chicago's Path to Operationalizing Decentralized Phase 1 Trials Across a Regional Network ACCC's Community Oncology Research Institute White Paper: Bringing Cancer Research to the Community:  Strategic Approaches to Representative Oncology Clinical Trial Design This podcast was created in partnership with the Decentralized Trials & Research Alliance, with support from Eli Lilly and Company, Gilead Sciences, and Merck.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über die Unitree-Euphorie, gute Gründe für Gold und die große Bitcoin-Shorts-Liquidierung. Außerdem geht es um Merck & Co., Qiagen, Sartorius, Infineon, SUSS MicroTec, CXMT, Marvell Technology, Alphabet, Broadcom, KraneShares China Technology & Semiconductor STAR 50 Index ETF (WKN: A3CU6C), Walmart, Alibaba, Baidu, Deere, Goldman Sachs, Royal Bank of Canada, Jefferies Financial Group, Evercore, Barclays, Morgan Stanley, DocMorris, Amazon, Redcare Pharmacy, iShares Global Infrastructure UCITS ETF USD (thesaurierend) (WKN: A3D6N1), iShares Global Infrastructure UCITS ETF USD (ausschüttend) (WKN: A0LEW9). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3… Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Trump is pausing a major tariff hike on Canadian imports after a tentative deal was reached, giving negotiators three more days to hammer out the details — including possible concessions on Keystone XL, autos, dairy, and alcohol.Plus, John Tavares is taking the CRA to court over an $8 million tax bill tied to his Maple Leafs signing bonus, in a case that could make it even harder for Canadian teams to attract top U.S.-based athletes.And in The Lab: Moderna and Merck report a major breakthrough for personalized mRNA cancer treatment after a late-stage trial showed their vaccine-and-immunotherapy combo could delay the return of melanoma.The Peak Daily is produced in partnership with reframevid.com

The US Treasury provided a boost to bond and equity markets yesterday, announcing that it will more than double repurchases of 10, 20, and 30-year debt in the next few months. This saw the long bond yield fall 10 bps from its 19-year high on Tuesday, to 5.184%. Gold had its best day since March. US stock markets also closed up on the day with Moderna and Merck providing a boost. Asian equity markets continued the rally overnight and the KOSPI leapt over 6% after SK Hynix announced a big stock buyback. Carsten Menke, Head of Next Generation Research, joins the podcast today to talk about gold and silver. Tune in to find out what he believes has been driving the August rally, and whether he thinks it can continue from here.(00:00) - Introduction: Helen Freer, Product & Investment Content (00:28) - Markets wrap-up: Bernadette Anderko, Product & Investment Content (06:49) - Gold and silver: Carsten Menke, Head of Next Generation Research (11:21) - Closing remarks: Helen Freer, Product & Investment Content Would you like to support this show? Please leave us a review and star rating on Apple Podcasts, Spotify or wherever you get your podcasts.

Digital Content Editor, Barbara Friedman, shared her top three stories trending online. Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour-long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30 am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Live from Washington, Vassy Kapelos checks in with CTV National News Senior Political Correspondent Mike LeCouteur for the latest on trade. We also pick the brain of Lisa Raitt, a former Conservative Cabinet Minister and a member of Prime Minister Carney's Advisory Committee on Canada-USA Economic Relations. On today's show: Dr. Bishal Gyawali, a Medical Oncologist and Professor of Medical Oncology at Queen's University, reacts to new progress from Merck and Moderna on potential mRNA cancer vaccines. Talk Science To Me with CTV Science and Technology specialist Dan Riskin: The science of writing your dating-app bio. The Daily Debrief Panel - featuring Robert Benzie, Laura Stone, Marieke Walsh, and Mike LeCouteur. Afua Hagan, CTV News' Royal Commentator, reacts to reports of Prince Harry and Meghan Markle returning to the United Kingdom.

P.M. Edition for Aug. 19. Today the total U.S. debt passed $40 trillion. WSJ economics reporter Matt Grossman discusses what that means for how the government functions. Plus, a successful trial of a mRNA vaccine for melanoma could mean potential new treatments for a deadly cancer–and news of the trial results more than doubled Moderna's stock price. And the Federal Trade Commission says retailers have to let shoppers know when they're using their personal data to raise prices. Dave Michaels, who covers corporate law enforcement for the Journal, explains how personalized pricing works, and how the FTC is looking to rein it in. Alex Ossola hosts. How Governments in the U.S. and Europe Are Stalling the AI Buildout Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Yields and the dollar moving sharply lower after the U.S. Treasury pledged to step up debt buybacks. The traders debate whether the move just gave stocks the all-clear. Then, Mizuho's Jared Holz reacts to the huge moves higher in Moderna and Merck, after the pair's personalized cancer vaccine succeeded in a pivotal  trial. Plus, new signs OpenAI is falling behind Anthropic, Target delivers a bullseye for investors and a humanoid robot maker's massive Shanghai debut. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Moderna and Merck just posted the first successful late-stage trial of a personalized mRNA cancer vaccine, intismeran paired with Keytruda, cutting the return and spread of high-risk melanoma, and Erick Erickson spends the hour singing the praises of Big Pharma and taking apart the conspiracy that drug companies are hiding the cure for cancer. He […]

Merck and Moderna have announced that a new mRNA vaccine has succeeded in blocking the return of one of the deadliest cancers. Wall Street Journal reporter Xavier Martinez explains more about the trial and why its giving cancer researchers hope.Then, primaries are underway, and in many races, progressives are prevailing. David Hogg, a progressive Democrat and president of Leaders We Deserve, shares his thoughts on primary results and why he's pushing party leaders to go with younger candidates.And, during the devastating Eaton fire in California, Nikki High turned her bookstore in Pasadena into a hub for mutual aid. High talks about the lessons she learned about community and resistance during that time.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

The Nasdaq, S&P 500, and Dow all rose roughly a fifth of a percent. Plus: Moderna stock skyrocketed nearly 177% after an experimental vaccine's success in a study. Pierre Bienaimé hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Target's second-quarter sales suggest the retailer's turnaround is working. And Cantor Fitzgerald plans to give its hedge-fund clients access to Kalshi's prediction markets. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shares of Moderna and Merck are surging on positive results from a Phase 3 trial of a groundbreaking cancer treatment. After a decade in development, individualized mRNA “vaccines” and established cancer treatment Keytruda result in reduced risk of recurrence or death. Moderna CEO Stephane Bancel and Merck Research Laboratories president Dr. Dean Li discuss this pivotal moment in medicine and how it fits into the long term visions for both Merck and Moderna. CEO of design and coding platform Figma Dylan Field discusses his company's wild year as a public company and building public trust in AI. Plus, it was primary night for Democrats in Florida, investors are scrutinizing revenues from Anthropic and OpenAI, and shares of Unitree are surging in Shanghai, presenting a potential challenge to U.S.-based humanoid robotics.    Stephane Bancel & Dr. Dean Li - 15:13 Dylan Field - 33:35   In this episode: Dylan Field, @zoink Becky Quick, @BeckyQuick Andrew Ross Sorkin, @andrewrsorkin Katie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bond yields pull back after the Treasury doubles liquidity support for buybacks. Allianz's Mohamed El-Erian warns the recent turmoil could have big social and political consequences. Plus, Moderna and Merck rally on a major breakthrough for their skin cancer vaccine. And defense tech firm Lyntris makes its NYSE debut in a downsized IPO, with its CEO joining us to discuss the road ahead. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As shares of Moderna and Merck surge on new vaccine trial data, we speak to a top analyst about why he thinks the move higher is very difficult to rationalize. Then, Former CEA Chair Jason Furman discusses the Treasury Department's new debt buyback operations. Plus, we bring you the details of Chinese robotics company Unitree soaring in its public debut in Shanghai. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

One day after the 30-year yield hit fresh 2007 highs — and stocks extended their daily losing streak to three — Carl Quintanilla, Jim Cramer and David Faber led off the show with yields falling after the Treasury Department announced it would at least double the size of its government debt repurchases. The anchors delved into all things AI — from OpenAI reportedly lagging behind Anthropic on revenue growth, to midterm elections being impacted by the backlash against data centers. Moderna shares doubled and Merck shares rose sharply on late-stage trial results involving the companies' melanoma vaccine. Also in focus: Why Marvell shares surged; Toll Brothers beats; Reaction to retail earnings from the likes of Target, Lowe's and TJX.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Elizabeth Burton, Chief Strategist at Fortress Investment Group, assesses the broader investment landscape and where she sees opportunity as investors balance growth against emerging risks. Health care takes center stage as Courtney Breen of Bernstein breaks down developments involving Moderna and Merck and what they mean for biotech and pharmaceutical investors as both stocks soar following promising results in a late-stage trial. Moderna jumped nearly 200%. Lo Toney of Plexo Capital tackles a key question in the AI race: is OpenAI losing momentum? Our Eunice Yoon reports on a Chinese humanoid robotics company going public and what the deal reveals about China's ambitions in robotics and AI. Finally, Kate McShane of Goldman Sachs analyzes the latest retail movers, reacts to Target and previews Walmart earnings as investors search for fresh signals on the health of the consumer. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

About this episode:   This summer, Merck & Co. settled more than 200 lawsuits alleging that the company's HPV vaccine, Gardasil, caused cases of autoimmune conditions and fertility issues in young women. But that $50 million settlement is not an admission of fault on the part of the company or the vaccine. In this episode: Vaccine law expert Dorit Reiss details the lawsuits, including why evidence isn't stacking up for plaintiffs and how headlines about the dollar amount can misconstrue the facts of the case.   Guest:  Dorit Reiss, PhD, is an expert on vaccine policy and a professor of law at UC San Francisco. Host:  Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.  Show links and related content:  Merck to Settle Bulk of Gardasil Suits for About $50 Million—Bloomberg Kennedy played key role in Gardasil vaccine case against Merck—Reuters What VAERS Is (And Isn't)—Johns Hopkins Bloomberg School of Public Health The HPV Vaccine, 20 Years Later—Public Health On Call (August 2026) Vaccines 101: The Vaccine Injury Compensation Program—Public Health On Call (February 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.

Sierra Kile, daughter of late Cardinals pitcher Darryl Kile, and Meghan Burek, a representative from Merck, join Chris and Amy ahead of a special event at Busch Stadium this evening. Playing with Heart, is at Busch Stadium, raising awareness about bad cholesterol. Darryl died of a heart attack in his Chicago hotel room 24 years ago. PlayingWithHeart.com for more info.

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics to living a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Title: Beyond Cholesterol: The Heart Health Markers That Matter [0:00:00] – Intro: Lettuce Contamination, Social Media & Local Business Impact Discussion of “fear of lettuce,” limited to 15 states (not Tennessee) How social media amplifies food scares Local “Build a Salad” restaurant going out of business and timing around lettuce scare [0:04:39] – Back-to-School Immune Support: Oral Probiotics & Iodine Nasal Spray Back-to-school season and rise in colds/sicknesses Oral probiotics for kids: oral microbiome, throat/sinus benefits Iodine nasal spray for parents and teachers: safety, use during school/gym, personal routines of Ed and Clint [0:08:04] – Supplement Industry & Big Pharma Buyouts Thorne bought by Procter & Gamble for $3.8B History of pharma mocking “granola/hippie” supplement culture, now buying brands Many acquired supplement brands failing under pharma ownership Difference between pharma customers and nutraceutical users (education, mindset) Nutrition World's preference for privately owned brands [0:14:00] – Life Lessons from Flying & Racing: Doing the Hard but Right Thing Ed's story: practicing engine-out landings, re-learning best glide speed Insight: sometimes you must “point the nose down” (do the counterintuitive hard thing) to survive Clint's race-car analogy: “you go where you look” – look down the track, not at the wall [0:18:01] – Food Label Claims: Olive Oil vs. Avocado Oil Products UC Davis testing of products “made with olive oil” – most passed authenticity tests Avocado-oil-labeled products often failing purity tests Takeaway: be more skeptical of “made with avocado oil” claims [0:18:31] – Prostate Cancer & “Treating the Terrain,” Not Just the Tumor Dr. Gio (prostate-focused naturopath): focus on the ground cancer grows in Historical context from Stephen Paget's work on tumor “soil and seed” Lifestyle “soil-building” recommendations: Resistance training, walking 150 minutes/week Waist circumference < half your height Sleep, stress reduction, nutraceuticals, nutrient-dense diet [0:21:58] – Multivitamins, Carotid Stenosis & Functional Benefits COSMOS study: Centrum multivitamin and patients with carotid narrowing Reported improvements in physical function (walking, climbing stairs) and symptoms (shortness of breath, fatigue) Ed's extrapolation: better-designed multis (True Grace, Life Extension, etc.) likely offer even more benefit [0:22:30] – Post-Infectious Cough: Honey + Instant Coffee vs. Prednisone Double-blind RCT comparing: Honey + instant coffee paste Prednisone Guaifenesin Honey + instant coffee dramatically outperformed prednisone in reducing persistent cough frequency Discussion of guaifenesin's role, safety, and its regulatory history in health food vs. pharmacy channels [0:30:12] – Prednisone, COVID & Anxiety: Personal Case Story Guest Dr. Curt Dearing shares: Followed COVID protocol including prednisone Developed severe, prolonged anxiety afterward (twice) Realization that prednisone triggered it Ed's summary of prednisone side effects: bone loss, cataracts, muscle wasting, weight gain; okay short term, risky long term [0:33:30] – Cardiovascular Disease, Statins, & New Drug Lifendra (PCSK9 Inhibitor Pill) CV disease framed as leading cause of death for most people Introduction of Lifendra (oral PCSK9 inhibitor, from Merck) as “breakthrough” LDL-lowering drug Comparison with Repatha (injectable PCSK9 inhibitor) Curt's key points: Lifendra lowers LDL but does not show reduction in cardiovascular death, heart attack, or stroke (per Merck's own wording so far) Repatha's trial data: minimal impact on non-fatal events; no reduction in CV deaths vs. placebo Very high cost (~$300+/month out of pocket; heavy insurance burden) Critique of LDL obsession in cardiology Need to ask: Why is the cardiovascular system inflamed and oxidized? Ed & Curt's “terrain” model: Bad inputs: ultra-processed food, toxins, poor sleep, chronic stress, lack of sun/movement Missing inputs: nutrient-dense foods, minerals, omega-3s, organ meats, sunlight, sleep, movement Example of amlodipine: lowers BP numbers but may increase arterial calcification (calcium channel blocker) For people unwilling to change lifestyle, drugs may offer marginal benefit—but not true health [0:41:05] – Curt's Book & Lab Markers That Matter More Than LDL-C Curt's book: “Beyond Cholesterol: The Ultimate Guide to Testing and Supplements for Heart Health” Emphasis on better markers: ApoB, LDL particle size/number, calcium score, etc. Book's Amazon performance briefly noted (new release bestseller in its category) [0:44:32] – Alternatives to Statins & PCSK9s: Bergamot & Lifestyle Curt's hierarchy: Lifestyle (diet, exercise, stress, sleep) Targeted supplements like bergamot (citrus extract): lowers harmful particles such as ApoB and supports “good” LDL function Only then consider pharmaceuticals, and very selectively Skepticism about recommending Lifendra at all; strong bias toward non-drug approaches [0:45:28] – Dr. Wolfson, Mold, and Cardiovascular Terrain Ed & Curt's respect for Dr. Jack Wolfson, “The Natural Heart Doctor” Mention of mold as a major, under-recognized driver of cardiovascular disease Reference to Dr. Wolfson's educational resources and upcoming podcast plans [0:48:04] – Key Takeaways on Lifendra & Heart Prevention Strategy Lifendra will not fix: seed oils, glyphosate exposure, mold, bad sleep, chronic stress Terrain-building priorities: Real food, omega-3s, sunlight Toxin reduction Mitochondrial support Foundational supplements Contrast: drugs = band-aids with side effects; nutraceuticals = “side benefits” when used correctly [0:52:28] – Wrap-Up Ed mentions Sprouts selling lab-grown meat and his strong opposition Update on Oura Ring: now tracking nighttime blood pressure and importance of BP dipping Listener story: young man post–heart surgery credits Nutrition World's education and support with changing his life Final thanks to Dr. Dearing and closing outro  The post Radio Show / Podcast – August 9, 2026 first appeared on Vital Health Radio.

US VP Vance said negotiations with Iran will take some time and that talks with Iran were 'messy', but will land in a 'good' place for the US.Iran's Deputy Foreign Minister said an understanding with Oman does not mean opening the Strait of Hormuz.Yemeni Houthis announced they targeted a Saudi oil vessel in the Gulf of Aden.Crude futures saw two-way trade and attempted to nurse some of the recent losses, in which Brent crude briefly returned to the USD 80/bbl territory.APAC stocks traded mostly lower following a similar performance stateside; European equity futures indicate a mildly positive cash market open.Looking ahead, highlights include Swedish Inflation (Jul), German Factory Orders (Jun), US Challenger Job Cuts (Jul), Initial Jobless Claims (Aug/01), Revelio PLS (Jul), Atlanta Fed GDP (Q3), CNB Policy Announcement (Aug), Banxico Policy Announcement (Aug). Speakers include Fed's Daly & Musalem. Supply from Spain & France. Earnings from ConocoPhillips, Fiserv, Rheinmetall, Merck & Diageo.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry. One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in stabilizing kidney function decline in patients with immunoglobulin A nephropathy (IgAN). In a Phase 3 trial, patients exhibited kidney function comparable to that of healthy adults. IgAN is a challenging autoimmune condition often leading to end-stage renal disease. This advancement, leveraging a monoclonal antibody to target specific pathways, could mark a new era in managing this chronic kidney disease. In oncology, Jiangsu Alphamab Biopharmaceuticals has been making waves through strategic collaborations, securing deals worth $125 million upfront and potential milestone payments reaching over $2 billion. Their focus on developing antibody-drug conjugates (ADCs) using AI and machine learning underscores the promise of precision oncology. ADCs marry the targeting precision of antibodies with potent anti-cancer drugs, highlighting robust investment and confidence in these cutting-edge therapies. Merck & Co. continues to expand its financial outlook, driven by the success of its flagship drugs like Keytruda. This monoclonal antibody remains pivotal in cancer immunotherapy, while drugs like Winrevair and Lipfendra are broadening Merck's reach into cardiovascular health. This growth trajectory reflects a strategic push toward diversifying product lines and leveraging breakthrough therapies to maintain strong financial performance. Additionally, Merck's $10.8 billion acquisition of Prometheus Biosciences aims to expand their therapeutic portfolio with targeted biologics. Although mid-stage trials showed mixed results for their anti-TL1A antibody therapy, such acquisitions are pivotal in addressing unmet medical needs. On the regulatory side, Sanofi's MenQuadfi vaccine has achieved EU approval for use in infants as young as six weeks. This approval enhances preventive measures against invasive meningococcal disease in vulnerable populations, representing a significant public health advancement. In research methodologies, Sethera Therapeutics' collaboration with Receptor.AI is notable. By integrating AI-driven platforms for polymacrocyclic peptide discovery aimed at hard-to-drug targets, they're paving the way for overcoming traditional drug discovery challenges through computational tools. However, not all news is about progress. Jazz Pharmaceuticals faced a setback by withdrawing its label indication for Zepzelca after failing Phase 3 trials for small-cell lung cancer. This underscores the inherent risks in clinical development pathways. From a financial standpoint, BioNTech has adjusted its 2025 sales forecast downward due to waning global demand for COVID-19 vaccines—a reflection of the volatile vaccine markets post-pandemic peaks. Meanwhile, Pfizer's discontinuation of its Phase 2 GIPR antagonist for obesity illustrates strategic pivots within R&D pipelines as companies reassess priorities based on trial outcomes and market potential. Recent corporate strategies include Pfizer's ambitious cost-saving plan totaling $9.7 billion through 2029. Amid economic pressures and patent expirations looming on key products like Eliquis, Pfizer is optimizing operations to stay competitive. Speculation around a possible merger between Bristol Myers Squibb (BMS) and AstraZeneca has stirred interest. With both facing patent cliffs, this merger could rejuvenate portfolios—though the strategic benefits for AstraZeneca are still debated. On the technological front, advancements in cellular therapies promise to revolutionize medicine production at the cellular level, potentially enhancing patient outcomes through more personalized treatments. The regulatory landscape is also evolving. There's a growing call for streamlining Investigational New Drug applications under the FDA's Trialblazer initiative—crucial for accelerating clinical trials and bringing innovative therapies to market swiftly. Finally, initiatives such as Boston Scientific's restructuring efforts highlight challenges within the medical device sector as companies adapt to shifting market dynamics. Overall, these developments underscore an industry in motion where innovation and adaptation are key to navigating complex landscapes and advancing patient care globally. As we look ahead, these trends will likely continue shaping the future of pharmaceuticals and biotech in profound ways.Support the show

SpaceX on the move in after-hours trading on the back of its first earnings report since going public. Can investors expect SpaceX to blast off, or will the aerospace giant sink even further below its IPO price?Then, major Pharma earnings from giants like Pfizer and Merck beating Wall Street estimates with Amgen and Eli Lilly on deck. Founder and CEO of Portal Innovations John Flavin lays out the best trades in the Pharma market, and his reaction to Novo Nordisk's slide after disappointing guidance. Plus, why Morgan Stanley is bearish on AMD, digging into Caterpillar earnings, and can McDonald's make a comeback? Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jenny Horne dives into the latest quarterly figures from fast food giant McDonald's (MCD). She points to a revenue miss and breaks down the domestic versus international operations for the Golden Arches. Meanwhile, Jenny takes a look at Merck's (MRK) oncology drug strength as a key part of its post-earnings move.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

US President Trump said the Iran conflict was working out very well and that Iran talks are going on now, and that they are talking about having the Strait open by Tuesday.US officials said there were no ‘new' or novel negotiations planned, only the ongoing talks between the US and Iranian teams through mediators, according to CBS News citing sources.A US base in Kuwait was reportedly struck; UKMTO received a report of an incident 20 nautical miles northeast of Oman's Al Khasab.10yr JGB futures saw two-way trade, in which it briefly fell over 60 ticks on a weak 10yr JGB auction, before trimming losses.APAC stocks traded mixed after the region failed to sustain the momentum from Wall Street; European equity futures indicate a positive cash market open.Looking ahead, highlights include US/Canadian Trade Balance (Jun), US JOLTS (Jun), Atlanta Fed GDP (Q3), New Zealand Jobs Report (Q2). Comments from Fed's Paulson. Supply from the UK & Germany. Earnings from Pfizer, Caterpillar, Merck, AMD, SpaceX, BP & Zalando.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

A US base in Kuwait was reportedly struck; UKMTO received a report of an incident 20 nautical miles northeast of Oman's Al Khasab. Additionally, a dry bulk carrier was reportedly hit by a projectile near the Strait of Hormuz. Iranian President said Tehran would defend its borders but does not seek to expand the war, according to state media.10yr JGB futures saw two-way trade, in which it briefly fell over 60 ticks on a weak 10yr JGB auction, before trimming losses.US equity futures are modestly higher, with PLTR and ON benefiting from strong earnings.DXY regains the 100.00 handle, USD/JPY nears 158.00 as 155.00 becomes the new floor.Energy benchmarks continue to climb amid US-Iran uncertainty.Looking ahead, highlights include US/Canadian Trade Balance (Jun), US JOLTS (Jun), Atlanta Fed GDP (Q3), New Zealand Jobs Report (Q2). Comments from Fed's Paulson. Earnings from Pfizer, Caterpillar, Merck, AMD & SpaceX.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Artificial Sweeteners & Cognitive Decline, Myosteatosis on Coronary CT, Merck's Oral PCSK9 Inhibitor, Cyclospora Outbreak, Gut-Brain Synchronization, and the Banana Smoothie Mistake Explained Artificial Sweeteners Linked To 62% Faster Cognitive Decline In Landmark Brazilian Study A study tracking more than 12,700 adults (average age 52) over eight years found that people consuming the most artificial and low-calorie sweeteners, roughly 191 mg a day, about what's in a single can of diet soda, showed cognitive decline 62% faster than the lowest-intake group, equivalent to 1.6 extra years of brain aging, with memory hit hardest. Six of the seven sweeteners tested, including aspartame, saccharin, and acesulfame K, were linked to faster decline; tagatose was the lone exception. Researchers point to gut-microbiome disruption, altered glucose and insulin signaling, and possible direct neuronal effects as plausible mechanisms. Host Dave Asprey breaks down why a dose this small was enough to move the curve, why tagatose deserves more scrutiny before being called "safe," and where diet products' short-term weight-loss marketing conveniently ignores the long-term cost to your brain. Source: https://www.inc.com/kevin-haynes/study-links-cognitive-decline-to-surprisingly-small-daily-amount-of-artificial-sweeteners/91376522 ~~ AI Analysis Of 1,722 Heart Scans Finds Muscle Quality Predicts Heart Attacks Independent Of Calcium Score Using data from the SCOT-HEART trial, a University of Edinburgh team ran an AI model against ten years of coronary CT angiogram scans, measuring skeletal muscle attenuation, a marker of myosteatosis, or fat infiltration into muscle tissue. Every 10-point increase in muscle density corresponded to a 31% lower heart attack risk and 39% lower all-cause mortality over the following decade, and critically, this held independent of coronary calcium score, the current gold-standard risk marker. The same low-density-muscle patients also showed higher lung attenuation, lower liver attenuation, and more torso fat volume, a pattern consistent with systemic insulin resistance rather than a muscle-specific issue. Host Dave Asprey unpacks why calcium score isn't capturing the full risk picture, why myosteatosis is really a readout of whole-body insulin sensitivity, and what he'd add to a routine workup on top of a calcium score. Source: https://www.theguardian.com/science/2026/jun/30/strong-chest-back-less-likely-heart-attack-analysis ~~ FDA Approves First Oral PCSK9 Inhibitor, Cutting LDL By Up To 60% Without Injections Merck's enlicitide (brand name Lipfendra) is now FDA-approved as the first once-daily oral PCSK9 inhibitor, lowering LDL cholesterol by up to 60% in a phase 3 trial of 2,912 patients, routinely bringing levels down to 50-60 mg/dL. It works by blocking PCSK9, a liver protein that tags LDL receptors for destruction, the same target as injectable drugs like Repatha and Praluent, which have shown roughly 20% reductions in heart attacks and strokes in high-risk patients. Lipfendra is priced at $315 for a 30-day supply, with no excess side effects reported versus placebo over six months, though long-term outcome data is still pending. Host Dave Asprey explains why crushing total LDL without checking ApoB, LDL particle number, or oxidized LDL is optimizing the wrong variable, and what he'd want on his labs before considering a drug like this. Sources: https://www.nytimes.com/2026/07/16/science/the-fda-approves-a-new-pill-to-slash-cholesterol-levels.html https://www.cnbc.com/2026/07/16/mercks-cholesterol-pill-gets-us-fda-approval.html ~~ Cyclospora Outbreak Tied To Taylor Farms Lettuce Spreads To 34 States, Prompts Nationwide Recall Federal investigators have linked a multistate cyclosporiasis outbreak to shredded iceberg lettuce from Taylor Farms de Mexico, with Michigan alone logging over 5,000 cases and 100+ hospitalizations, much of it traced to lettuce used at Taco Bell. Taylor Farms has recalled all iceberg lettuce sourced from central Mexico, and Walmart has pulled Marketside Iceberg Salad and Marketside Shredded Lettuce with specific date codes across 27 states. Cyclospora spreads through fecal contamination and causes weeks of watery, explosive diarrhea if untreated; washing doesn't reliably eliminate it, since the parasite requires heat above 158°F to inactivate. Host Dave Asprey explains why pre-washed, pre-cut bagged greens remain a recurring contamination risk no matter what the label claims, and connects the outbreak's gut damage to lingering gut-brain consequences long after symptoms resolve. Sources: https://www.usatoday.com/story/news/health/2026/07/18/taylor-farms-shredded-lettuce-sample-cyclospora/90969103007/ https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-5-state-outbreak-cyclospora-illnesses-iceberg-lettuce-july-2026 ~~ New Research Links Excessive Gut-Brain Synchronization To Anxiety And Depression Emerging research on the enteric nervous system, which contains over 100 million neurons and sends more signals to the brain than it receives, finds that when the gut's electrical rhythm synchronizes too tightly with the brain's, that over-coupling correlates with higher rates of anxiety and depression. The gut communicates with the brain through the vagus nerve, hormones, and immune signaling, and dysbiosis or ENS dysfunction has separately been linked to mood disorders in both human and animal studies. Host Dave Asprey breaks down why the goal isn't maximum gut-brain connection but the right kind of connection, questions whether the coupling is driving the anxiety or the anxiety is driving the coupling, and makes the case for treating mood from the gut up instead of the brain down. Source: https://refractor.io/medical/enteric-nervous-system-brain-link-mental-health/ ~~ Rhonda Patrick Explains Why She Never Adds Bananas To Her Berry Smoothies Rhonda Patrick has been telling audiences she skips bananas in her berry smoothies because of polyphenol oxidase, an enzyme in bananas that degrades the polyphenols in blueberries linked to improved cognition and vascular health, based on in-vitro and food chemistry data. She now builds her smoothies on an avocado base instead, and notes that vitamin C from citrus can partially inhibit the enzyme for anyone unwilling to drop the banana. Host Dave Asprey weighs in on the gap between lab chemistry and clinical outcome data, why that gap doesn't make the mechanism any less real, and why this is a low-cost swap worth making even without a human trial behind it. Sources: https://www.reddit.com/r/Biohackers/comments/1v2jbib/dr_rhonda_patrick_i_dont_add_bananas_to_my/ https://www.foundmyfitness.com/episodes/polyphenol-oxidase-bananas-smoothies ~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insight into a sweetener risk hiding in everyday diet products, a heart attack predictor buried inside routine CT scans, the tradeoffs of a new cholesterol drug, a produce recall worth paying attention to, the science behind gut-driven anxiety, and a smoothie mistake that's quietly undercutting your polyphenol intake. Host Dave Asprey connects clinical research, cohort data, and food chemistry into practical frameworks for protecting brain health, cardiovascular health, and gut-brain resilience. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: artificial sweeteners cognitive decline, aspartame brain aging, tagatose safety, diet soda memory loss, myosteatosis coronary CT, skeletal muscle attenuation heart attack, SCOT-HEART trial, coronary calcium score insulin resistance, enlicitide Lipfendra FDA approval, oral PCSK9 inhibitor, LDL particle number ApoB, cyclospora outbreak 2026, Taylor Farms lettuce recall, cyclosporiasis symptoms treatment, enteric nervous system anxiety, gut brain synchronization, vagus nerve mental health, Rhonda Patrick polyphenol oxidase, banana blueberry smoothie mistake, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Suppgrade Labs | Get real restorative sleep with Quiet Mode. Use code DAVE15 at shopsuppgradelabs.com. - EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE for 40% off. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:19 – Story 1: Artificial Sweeteners 02:05 – Story 2: Muscle Fat & Heart Risk 04:36 – Story 3: PCSK9 Cholesterol Pill 06:27 – Story 4: Cyclospora Lettuce Outbreak 07:56 – Story 5; Gut-Brain Axis & Anxiety 09:29 – Story 6: Banana vs. Blueberry 11:08 – Predictions for Next 5 Years See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. ·       How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 ·       How can we effectively onboard APPs? 10:24 ·       Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 ·       What models have worked well for deploying APPs into GI practices? 24:32 ·       What strategies are most effective for APP retention? 29:07 ·       How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc.  Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.

The Pirate Street Journal takes a sharp look at business through the category design lens, and this episode delivers three stories that reveal how the decisions made today will define economic winners and losers for decades. From data center legislation in New York to Apple raising prices and a Costco cashier becoming a millionaire, each story points to the same underlying truth: the category you choose matters more than almost anything else. Whether you are a governor, a tech executive, or an hourly worker, picking the right side of the S-curve is everything. This is just one of the topics that Pirates Christopher Lochhead, Eddie Yoon and Bri Clark discuss on this episode of Pirate Street Journal. Each week, the Category Pirates pick three headlines worth paying attention to and break down the category underneath. You're listening to Christopher Lochhead: Follow Your Different. We are the real dialogue podcast for people with a different mind. So get your mind in a different place, and hey ho, let's go.   New York Said No to Data Centers and It Will Pay the Price On July 10th, New York became the first state in America to ban new data centers, with Governor Kathy Hochul signing a freeze on permits for hyperscale facilities for up to a full year. She cited higher power bills, water use, and grid strain as her reasons. Meanwhile, legislation is already being introduced to extend that freeze to three years. This is happening at the same time a study revealed New York has lost $11 billion in taxes due to millionaires leaving the state, and the city recently implemented rent control that has effectively killed new housing development. Compare that to Boise, Idaho, where four people started a memory chip company called Micron in the basement of a dental office back in 1978. Today, Micron employs more than 6,000 people, stands as the third largest private employer in Idaho, and just committed to a $15 billion expansion, the largest private investment in the state’s history. One town said yes 48 years ago and is still cashing that check. The next Boise could be anywhere someone decides to welcome the future, including, perhaps, the Big Island of Hawaii. The smarter move for any governor would not be a blanket freeze but a proof of concept, a small data center pilot that generates real-world data instead of relying on academic spreadsheets. Governors today have more power and agency than they may realize, and the choice between welcoming AI infrastructure or blocking it is really a choice between the future and the past.   Apple’s Price Hikes Signal the Return of On-Premise AI Apple recently raised prices across its lineup, with the Mac Studio jumping $1,300 and even entry-level MacBooks climbing $100. Tim Cook called the memory shortage a hundred-year flood, and he is not entirely wrong. DRAM and NAND prices surged roughly 60% last quarter and are projected to climb another 13 to 18% this quarter, with some analysts expecting memory costs to double again before the cycle ends. The AI hardware boom is still in its early innings, and anyone due for an upgrade should know that prices are only heading one direction. But the deeper story here is about data ownership and the return of on-premise computing. When businesses send their data into cloud-based AI platforms, those platforms can see everything. The controversy around Anthropic launching a product that competed directly with Cursor, a development tool built on top of Anthropic’s cloud, illustrated exactly why enterprises cannot afford to hand over their intellectual capital. Goldman Sachs, Merck, Citibank, none of them can afford to have an AI provider see their most sensitive work and potentially act on it. Apple’s privacy-first approach and its push to run more AI directly on device is not just a marketing position. It is a strategic response to a real problem. As LLMs commoditize, Apple is positioning itself as the gateway that routes your queries to the right model for the right task, while keeping your data on your device and out of someone else’s servers. Dell is also worth watching here, as its infrastructure business is growing at 40% while its consumer hardware grows at just 5%, a clear signal that the on-prem shift is accelerating.   The Costco Cashier Proves Category Kings Build Millionaires The Wall Street Journal ran a story about a Costco cashier who makes $32.90 an hour, started at $5.85 back when it was still Price Club, owns a three-bedroom home with a pool, and has a 401(k) worth over one million dollars. He is not an outlier. Costco’s CFO confirmed that many thousands of their hourly workers have crossed the seven-figure mark in retirement savings, and the company’s annual turnover sits at just 7% compared to a retail industry average of 60%. This story is really about category design in action. Costco became a category king in retail by capping its markups at 15% when every other retailer was charging 35 to 40%, offering generous health benefits even to part-timers, and building a culture that retains people for decades. When you combine low turnover with a growing stock, mission-driven leadership, and a business model that serves customers, employees, and investors simultaneously, you get the kind of compounding wealth that turns a cashier into a millionaire. The lesson applies whether you are scanning groceries or launching a startup. The category you pick matters more than the salary on your offer letter. Finding a company on the left side of the S-curve, one that treats its customers, its people, and its investors well while still growing, is the real career decision. The title and the paycheck matter far less than whether the category you join is heading toward abundance or quietly flatlining on the way down. To hear about all the topics in this week's The Pirate Street Journal, download and listen to this episode. You can also read more Pirate Street Journal entries in the Category Pirates newsletter.   We hope you enjoyed this episode of Christopher Lochhead: Follow Your Different™! Christopher loves hearing from his listeners. Feel free to email him, connect on Facebook, X (formerly Twitter), LinkedIn, and subscribe on Apple Podcast / Spotify!